https://scholars.lib.ntu.edu.tw/handle/123456789/550168
標題: | Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year | 作者: | Hsiao S.-M. HO-HSIUNG LIN Kuo H.-C. |
公開日期: | 2018 | 出版社: | Blackwell Publishing | 卷: | 10 | 期: | 1 | 起(迄)頁: | 21-26 | 來源出版物: | LUTS: Lower Urinary Tract Symptoms | 摘要: | Objectives: Details on the therapeutic effects of long-term antimuscarinic therapy have not been reported. Thus, the aim of this study is to evaluate the detailed long-term therapeutic effect of antimuscarinic therapy. Methods: All consecutive patients who visited the urologic outpatient clinics of a medical center for treatment of overactive bladder syndrome and received antimuscarinic therapy of 12 months or more were retrospectively reviewed. All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit. Results: A total of 140 patients had received 12 months or more of antimuscarinic therapy. Sustained therapeutic effects were observed by persistent decreases of IPSS-storage score, IPSS-total score and OABSS score. Moreover, the maximum flow rate did not change over time. A temporary increase in postvoid residual volume and decrease in voiding efficiency were found, but these parameters improved over long-term visits. Side-effects were observed in 81 patients (57.9%) and included dry mouth (n = 58, 41.4%), constipation (n = 48, 34.3%) and blurred vision (n = 4, 2.9%); all side-effects were tolerable. Patients aged 75 years or more (n = 94) had a higher comorbidity rate (n = 46, 48.9%) before treatment but generally exhibited similar therapeutic effects as overall patients; elderly patients could also tolerate side-effects. Conclusion: Sustained therapeutic effects were observed in patients who received 12 months or more of antimuscarinic therapy, even in elderly patients. In addition, side-effects in patients receiving long-term therapy were also common but tolerable. ? 2016 John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992460217&doi=10.1111%2fluts.12136&partnerID=40&md5=41fbeb48bee71a81e844a4ed797e90df https://scholars.lib.ntu.edu.tw/handle/123456789/550168 |
ISSN: | 1757-5664 | DOI: | 10.1111/luts.12136 | SDG/關鍵字: | oxybutynin; solifenacin; tolterodine; mandelic acid derivative; muscarinic receptor blocking agent; oxybutynin; solifenacin; tolterodine; adult; aged; Article; blurred vision; comorbidity; constipation; drug effect; drug tolerability; female; groups by age; human; International Prostate Symptom Score; long term care; major clinical study; male; micturition disorder; overactive bladder; Overactive Bladder Symptom score; postvoid residual urine volume; priority journal; retrospective study; scoring system; treatment duration; treatment outcome; urine flow rate; uroflowmetry; very elderly; xerostomia; adolescent; chemically induced; constipation; middle aged; overactive bladder; pathophysiology; severity of illness index; time factor; treatment outcome; urodynamics; visual disorder; xerostomia; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Retrospective Studies; Severity of Illness Index; Solifenacin Succinate; Time Factors; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Vision Disorders; Xerostomia; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。